Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	CSF2	Synonyms	CSF, GMCSF	Type of gene	protein-coding
Chromosome	5	Map location	5q31.1	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas
Description	colony stimulating factor 2

Gene symbol	E2F1	Synonyms	E2F-1, RBAP1, RBBP3, RBP3	Type of gene	protein-coding
Chromosome	20	Map location	20q11.22	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	E2F transcription factor 1

GTO ID	GTC3966
Trial ID	NCT04452591
Disease	Bladder Cancer
Altered gene	E2F1\|CSF2
Therapeutic/Target gene	Therapeutic gene
Therapy	DNA oncolytic virus
Treatment	CG0070\|Cretostimogene Grenadenorepvec
Co-treatment	n-dodecyl-B-D-maltoside
Phase	Phase3
Recruitment status	Recruiting
Title	A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
Year	2020
Country	United States\|Australia\|Japan\|Korea, Republic of\|Taiwan
Company sponsor	CG Oncology, Inc.
Other ID(s)	CG3002S

Vector information

Vector	adenovirus
Construct	Ad5-E2F-E1A-GMCSF
Vector type	a first generation, replication-defective adenovirus serotype 5 (Ad5) vector
Transgene/Inserted gene	the human GM-CSF cytokine gene
Regulatory element	E2F-1 promoter
Viral genome modification	Ad5 adenovirus was engineered with the human E2F-1 promoter driving the E1A gene, and the human GM-CSF gene inserted.
Additional feature	GM-CSF

Clinical Result

Cohort1: All Countries

Administration route	intravesical injection
Dosage	Cretostimogene, weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6
Age	Adult, Older_Adult

Cohort2: Japan and United States Only

Administration route	intravesical injection
Dosage	Cretostimogene, 1E12vp IVE, weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6
Age	Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph